Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years.

Viking Therapeutics (NASDAQ: VKTX), a biotech that has shot to prominence thanks to a weight-loss drug it is developing, was ...

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

Fintel reports that on April 28, 2025, Cantor Fitzgerald initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a ...

Like Altimmune, Viking has a promising pipeline candidate targeting MASH, which is also known as nonalcoholic steatohepatitis. The company reported positive phase 2 results for its MASH drug, VK2809, ...

Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.86. The company has a 50 day moving average price of $26.47 and a 200 day moving average price of $40.34. Insiders Place ...

Shares of NASDAQ:VKTX opened at $25.94 on Monday. The stock has a market capitalization of $2.91 billion, a PE ratio of -25.94 and a beta of 0.84. Viking Therapeutics has a 1 year low of $18.92 ...

Big pharmaceutical companies as well as smaller biotechs have been hoping to score a win in one of today's highest-growth ...

Viking's Q1 earnings show no revenue, increased R&D spending, and a substantial cash reserve, positioning it well for future ...

Viking Therapeutics reports quarterly losses of 41 cents per share, which missed the analyst consensus estimate of losses of 34 cents. The company says the increase in the quarterly net loss ...

Viking Therapeutics VKTX is set to give its latest quarterly earnings report on Wednesday, 2025-04-23. Here's what investors need to know before the announcement. Analysts estimate that Viking ...

Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $23.94, demonstrating a +1.44% swing from the preceding day's closing price. The stock outperformed the S&P 500, which ...